

# europaean journal of gynaecological oncology

an International Journal

*Editors-in-Chief*

**A. Onnis** **P. Bószé**  
*Montréal (Canada) Budapest (Hungary)*

*Associate Editor*

**M. Marchetti**  
*Padua (Italy)*

*Assistant Editor*

**J. Wilson**  
*San Diego - CA (USA)*

*Editorial Board*

H. H. Allen, <i>London, Ontario (Canada)</i>	A. F. Fuller Jr., <i>Boston, MA (USA)</i>	J. Menczer, <i>Savyon (Israel)</i>
S. O. Anteby, <i>Jerusalem (Israel)</i>	H. E. Geisler, <i>Indianapolis, IN (USA)</i>	J. Monsonego, <i>Paris (France)</i>
P. Audet-Lapointe, <i>Montreal (Canada)</i>	A. Gerbault, <i>Villejuif (France)</i>	A. Pinotti, <i>São Paulo (Brasil)</i>
L. Aurelian, <i>Baltimore, MD (USA)</i>	A. Gorins, <i>Paris (France)</i>	S. M. Piver, <i>Buffalo, NY (USA)</i>
A. Ayhan, <i>Ankara (Turkey)</i>	A.P.M. Heintz, <i>Utrecht (The Netherlands)</i>	S. Rakar, <i>Ljubljana (Slovenia)</i>
O. Balat, <i>Graziantep (Turkey)</i>	L. Ioannidou-Mouzaka, <i>Athens (Greece)</i>	K. S. Raju, <i>London, England (UK)</i>
H. K. Barber, <i>New York, NY (USA)</i>	A. I. Karseladze, <i>Moscow (Russia)</i>	J. H. Shepherd, <i>London, England (UK)</i>
A. Basta, <i>Krakow (Poland)</i>	J. Klastersky, <i>Bruxelles (Belgium)</i>	P. Sismondi, <i>Turin (Italy)</i>
H. C. Bender, <i>Dusseldorf (Germany)</i>	V. Kozachenko, <i>Moscow (Russia)</i>	J. Stelmachów, <i>Warsaw (Poland)</i>
P. L. Benedetti Panici, <i>Rome (Italy)</i>	B. Kralj, <i>Ljubljana (Slovenia)</i>	L. Ungár, <i>Budapest (Hungary)</i>
T. Charkviani, <i>Tbilisi (Georgia)</i>	E. Kubista, <i>Vienna (Austria)</i>	I. Vergote, <i>Leuven (Belgium)</i>
D. Dargent, <i>Lyon (France)</i>	A. P. Kudelka, <i>Houston, TX (USA)</i>	J. B. Vermorken, <i>Edegem (Belgium)</i>
C. F. De Oliveira, <i>Coimbra (Portugal)</i>	T. Maggino, <i>Padua (Italy)</i>	P. Vîrtej, <i>Bucharest (Romania)</i>
S. Dexeus Jr., <i>Barcelona (Spain)</i>	J. Markowska, <i>Poznan (Poland)</i>	P.-H. Wang, <i>Taipei (Taiwan)</i>
G. De Palo, <i>Milan (Italy)</i>	C. Marth, <i>Innsbruck (Austria)</i>	R. Winter, <i>Graz (Austria)</i>
G. R. Di Paola, <i>Buenos Aires (Argentina)</i>	Leon F. A. G. Massuger, <i>Nijmegen (The Netherlands)</i>	Y. Yokoyama, <i>Hirosaki (Japan)</i>
F. Di Re, <i>Milan (Italy)</i>		J. Zielinski, <i>Warsaw (Poland)</i>
P. Di Saia, <i>Orange, CA (USA)</i>		
S. K. Fotiou, <i>Athens (Greece)</i>		

*Publisher Organization:*

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc  
Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)  
Tel. +514-4893242-4893640 - Fax +514-4854513 - E-mail: canlux@qc.aira.com  
www.irog.net

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

# European Journal of Gynaecological Oncology

www.irog.net

## General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

### AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

**ANNOUNCEMENTS** regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

**BOOK SAMPLES** for review should be sent to the Editorial offices in Montréal or in Padova.

**COPYRIGHT:** the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

**ADVERTISING INFORMATION:** advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H5, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@qc.aira.com - www.irog.net.

**RESPONSABILITY:** although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

### SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

**Subscriptions are entered with prepayment only.** The annual subscription is \$390 US for Institutions, \$260 US for Individuals and \$120 US for Members of Societies of Gynaecological Oncology all over the world. For airmail add \$30. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.**

**Claims** for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

# European Journal of Gynaecological Oncology

## Instructions to Authors

### SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storie 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, PO Box 46, 1031 Budapest, Hungary, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@mail.matav.hu.

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

**Publication time will be the shortest possible** based on scientific and publishing needs. **Manuscripts submitted for publication cannot be returned.**

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

### MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts*, typed and double spaced should be submitted **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. Full-length *articles* should not exceed 8 printed pages including tables and references.

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: *Summary* (purpose of investigation, methods, results, conclusion - about 150 words), *Key words*, *Content* (a 20-word summary), *Introduction*, *Materials and Methods*, *Results*, *Discussion*, *Conclusion*, *Acknowledgement* (if any), *References*, *Tables*, *Legends*.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

*Authors* must give their complete professional identifications and affiliations, including all academic titles and positions.

In general, **no more than six authors is considered appropriate**. Authors' names cannot be changed after submission.

*Letters to the editor* should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

*Figures*: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

*Legends* should be typed on a separate page with Arabic numerals corresponding to the illustrations.

*Tables* should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

*References* should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

*Articles in Journals*: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

*Books*: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

*Acknowledgments* will be limited to appropriate professionals who were contributors to the paper.

**PROOFS** revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

### BUSINESS MATTERS

The Journal has no commercial advertisements.

**Authors will be expected to contribute to the printing expenses, tables, clichés and postage.** For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.**

*Reprints* should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

**Individual subscribers** are entitled to publish, once a year, works, no longer than **two** printed pages with 25 reprints, free of charge (excluding tables, figures, illustrations, postage), and to have discounts on additional pages and on reprints over the 25 provided free of charge. When the work is sent the Author needs to specify that he is a subscriber.

**EDITOR'S CORNER**

- The twentieth birthday of the European Society of Gynaecological Oncology (ESGO)** 105  
A. Onnis - *Montréal, CANADA*

**DISTINGUISHED EXPERT SERIES**

- Sentinel node biopsy for breast cancer: yes, less surgery is better surgery** 107  
P. Sismondi, R. Ponzzone, N. Biglia, R. Roagna, F. Cacciari, F. Maggiorotto - *Turin, ITALY*  
Sentinel node dissection is the new standard of care for node negative breast cancer patients, but several technical issues need further clinical validation.

**ORIGINAL ARTICLES**

- Identification of chemotherapeutic refractory cases based on human chorionic gonadotropin values among patients with low-risk persistent trophoblastic disease treated with 8-day methotrexate-folinic acid** 113  
T. Shigematsu, T. Hirakawa, H. Yahata, T. Sonoda, N. Kinukawa, H. Nakano - *Fukuoka, JAPAN*  
Identification of low-risk PTD patients refractory for 8-day methotrexate-folinic acid treatment based on post-treatment hCG values.
- Development of an evidence-based algorithm for the management of ovarian cancer** 117  
M. C. Shaw, C. D. A. Wolfe, O. Devaja, K. S. Raju - *London, UK*  
The development of an algorithm for ovarian cancer management and the level of supporting primary research evidence are described.
- Role of pelvic lymphadenectomy in the management of Stage I endometrial cancer: our experience** 126  
E. Vizza, G. M. Galati, G. Corrado, C. Sbiroli - *Rome, ITALY*  
The prognostic value of pelvic node removal on survival of patients affected by endometrial carcinoma at pre-surgical FIGO Stage I is estimated.
- Simultaneous immunohistochemical localization of  $\beta$ -catenin and cyclin D1 in differentiated but not in undifferentiated human endometrial carcinoma** 129  
F. Narita, A. Sato, S. Hamana, M. Deguchi, T. Otani, T. Maruo - *Kobe, JAPAN*  
Simultaneous expression of  $\beta$ -catenin and cyclin D1 was observed in differentiated human endometrial carcinomas but not in undifferentiated cases.
- Tamoxifen-induced endometrial cancer** 135  
P. Chen, C. C. Yang, Y. J. Chen, P. H. Wang - *Taipei, TAIWAN*  
Menopausal women (either spontaneous or chemotherapy induced) with breast cancer on tamoxifen treatment must be evaluated more carefully and frequently.
- ErbB-2/HER-2 protein expression, serum tumour necrosis factor- $\alpha$  (TFM- $\alpha$ ) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix** 138  
Z. Melczer, F. Bánhidly, S. Csömör, P. Siklós, O. Dworak, K. Cseh - *Budapest, HUNGARY*  
ErbB-2 expression is increased and connected with decreased TNF- $\alpha$  and soluble TNFR-2 levels in patients with cervical cancer.
- The assessment of stability and reliability of a virtual reality-based laparoscopic gynecology simulation system** 143  
W. H. Sung, C. P. Fung, A. C. Y. Chen, C. C. Yuan, H. T. Ng, J. L. Doong - *Chung-Li, Tao-Yuan and Taipei, TAIWAN*  
A virtual reality-based laparoscopic gynecology simulation system was developed for surgical training. The system is very stable and has a fair high test-retest reliability.
- Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection** 147  
M. Sikorski, H. Żrubek - *Lublin, POLAND*  
A 53% complete response rate and a 23.5% partial response rate have been achieved after intracervical interferon gamma administration in CIN I/II cases with HPV infection.
- Serum CA-125 tumor marker in endometrial adenocarcinoma** 151  
V. Kukura, G. Zovko, S. Ciglar, L. Markulin-Grgić, F. Šantek, M. Podgajski, Ž. Duić - *Zagreb, CROATIA*  
High CA-125 production is associated with increased metastatic potential of endometrial adenocarcinoma.
- Immunopathological study of mesonephric lesions of cervix uteri and vagina** 154  
A. Kondi-Pafitis, E. Kairi, K. I. Kontogianni, C. Dimopoulou, K. Sikiotis, V. Smyrniotis - *Athens, GREECE*  
Characteristics of mesonephric lesions of the vagina and cervix uteri are discussed.
- Human papillomavirus frequency of women at low risk of developing cervical cancer: a preliminary study from a Turkish university hospital** 157  
B. Özçelik, İ. S. Serin, S. Gökahmetoğlu, M. Başbuğ, R. Erez - *Kayseri, TURKEY*  
The frequency of HPV infection was found to be 6.1% among women at low-risk of developing cervical cancer in our region.

<b>Concurrent chemotherapy and radiotherapy for cervical cancer</b>	160
A. Martín-Martínez, F. Molano, M. Lloret, O. Falcón-Vizcaino, J. Á. García-Hernández - <i>Canaries, SPAIN</i>	
A combination of chemotherapy and radiotherapy for locally advanced cervical carcinoma as the treatment of choice is proposed.	
<b>Short duration neoadjuvant chemotherapy followed by radiotherapy for advanced carcinoma of the cervix: results and prognostic variables</b>	163
M. Seoud, F. B. Geara, A. Shamseddine, Z. Salem, A. Khalil - <i>Beirut, LEBANON</i>	
Short-duration neoadjuvant chemotherapy (bleomycin, cisplatin, vincristine) has been given to patients with advanced squamous cell carcinoma of the cervix followed by definitive radiation therapy. Although stage and response to neoadjuvant chemotherapy were significant prognostic factors, there was no obvious long-term survival benefit.	
<b>Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients</b>	169
T. Bilgin, S. Özalp, Ö. T. Yalçın, G. Zorlu, M. A. Vardar, K. Özerkan - <i>Bursa, TURKEY</i>	
Gemcitabine is an active drug with acceptable toxicity in ovarian cancer.	
<b>Survival and prognostic factors in patients with synchronous ovarian and endometrial cancers and endometrial cancers metastatic to the ovaries</b>	171
A. Ayhan, T. Guvenal, F. Coskun, M. Basaran, M. C. Salman - <i>Ankara, TURKEY</i>	
The characteristics of 53 patients with synchronous primary ovarian and endometrial cancer and 64 patients with endometrial cancer metastatic to the ovaries are evaluated.	
<b>Preoperative work-up of early cervical cancer (Stages Ib-IIa)</b>	175
F. Kokka, G. Vorgias, A. Tserkezoglou, I. Tsiaousi, G. Hadjieleftheriou, M. Andriotis, Th. Akrivos, S. Fotiou, N. Apostolikas - <i>Peireas and Athens, GREECE</i>	
Preoperative work-up of early cervical cancer in 309 patients is reported. CT proved adequate in evaluating the bladder and colon. Other tests can be performed when CT is suspicious of invasion.	
<b>High-risk human papillomavirus (HPV) types in patients with squamous intraepithelial lesions (SIL)</b>	178
M. V. Perovic, M. J. Berisavac, N. Kuljic-Kapulica, T. Jovanovic - <i>Belgrade, YUGOSLAVIA</i>	
Multiples infection with different HPV types are more often found in patients with LGSIL than in those diagnosed with HG-SIL.	
<b>Adding ketoprofen to intravenous patient-controlled analgesia with tramadol after major gynecological cancer surgery: A double-blinded, randomized, placebo-controlled clinical trial</b>	181
S. Tuncer, L. Pirbudak, O. Balat, M. Çapar - <i>Gaziantep and Konya, TURKEY</i>	
A double-blinded, randomized, placebo-controlled clinical trial, the efficacy and safety of ketoprofen, in addition to intravenous patient-controlled analgesia with tramadol after major gynecological cancer surgery are discussed.	
<b>Transvaginal sonography combined with saline contrast sonohysterography to evaluate the uterine cavity in patients with abnormal uterine bleeding and postmenopausal endometrium more than 5 mm</b>	185
M. Kazandi, S. Akşehirli, T. Cirpan, F. Akercan - <i>Izmir, TURKEY</i>	
Sonohysterography is a sensitive method, superior to transvaginal sonography in the evaluation of the uterine cavity in patients with abnormal uterine bleeding.	
<b>Radiochemotherapy for patients with locally advanced cervical cancer: early results</b>	191
Z. Özşaran, D. Yalman, V. Yürüt, A. Aras, A. Özşaran, M. Hanhan, A. Haydaroğlu - <i>Izmir, TURKEY</i>	
Concurrent chemoradiation for locally advanced cervical cancer is the treatment of choice in suitable patients providing high response rates with acceptable toxicity.	
<b>A safe method of gut resection in women with complicated post-radiation enteritis after cervix cancer</b>	195
V. Smyrniotis, G. Kostopanagiotou, E. Gamaletsos, K. Theodoraki, A. Kondi-Pafiti, N. Panagiotopoulos, J. Vassiliou, C. Sykiotis - <i>Athens, GREECE</i>	
The partial resection of the irradiated small bowel plus right colectomy, in order to leave parts of the small adherent bowel, is a safe, simple method and eliminates injuries to the adjacent structures.	
<b>CASE REPORTS</b>	
<b>Two twins with teratoma of the ovary. An unusual association: case report</b>	199
M. Indinnimeo, C. Cicchini, A. Larcinese, S. Kanakaki, F. Ricci, P. L. Mingazzini - <i>Rome, ITALY</i>	
This is the second report of two twins with ovarian teratoma suggesting the need of an accurate familial follow-up.	
<b>Uterine sarcoma associated with tamoxifen use: Case report</b>	202
M. Martín-Loeches, J. Rius, R. M. Orti - <i>Valencia, SPAIN</i>	
There is no doubt that all cases of endometrial thickening must be investigated in tamoxifen users.	
<b>Book Reviews</b>	204